Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) - a study protocol.

Abstract:

BACKGROUND:Patients with type 2 diabetes (T2D) are at increased risk for developing cancer. As approximately 8% of the world's population is living with T2D, even a slight increase in cancer risk could result in an enormous impact on the number of persons developing cancer. In addition, several glucose lowering drug classes for treating patients with T2D have been associated with a difference in risk of cancer overall, and especially for obesity related cancers. In what way and to what degree cancer risk is modified by the use of different sulfonylureas (SU) is unclear. The primary aim of this study will be to evaluate within-class SU differences in obesity related cancer risk. Secondary aims will be to investigate within-class SU differences in risk for all cancers combined and site-specific cancers separately (i.e. breast, colorectal, prostate, bladder and lung cancer) and to account for duration-response relationships between individual SU use and cancer risk. METHODS:Patients will be selected from a Dutch primary care cohort of patients with T2D linked with the Dutch Cancer Registration (ZODIAC-NCR). Within this cohort study annually collected clinical data (e.g. blood pressure, weight, HbA1c) and nationwide data on cancer incidence are available. Time-dependent cox proportional hazard analyses will be performed to evaluate SU cancer risk, adjusted for potential confounders. DISCUSSION:This study will be the first prospective cohort study investigating within-class SU differences in cancer risk and could contribute to improved decision making regarding the individual drugs within the class of SUs, and possibly improve quality of life and result in an increased cost-effectiveness of healthcare in patients with T2D. TRIAL REGISTRATION:Nederlands Trialregister ( NTR6166 ), 6 Jan 2017.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Schrijnders D,de Bock GH,Houweling ST,van Hateren KJJ,Groenier KH,Johnson JA,Bilo HJG,Kleefstra N,Landman GWD

doi

10.1186/s12885-017-3433-z

subject

Has Abstract

pub_date

2017-06-23 00:00:00

pages

444

issue

1

issn

1471-2407

pii

10.1186/s12885-017-3433-z

journal_volume

17

pub_type

临床试验,杂志文章
  • Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells.

    abstract:BACKGROUND:Pancreatic cancer remains the deadliest of all cancers, with a mortality rate of 91%. Gemcitabine is considered the gold chemotherapeutic standard, but only marginally improves life-span due to its chemical instability and low cell penetrance. A new paradigm to improve Gemcitabine's therapeutic index is to a...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-419

    authors: Papa AL,Basu S,Sengupta P,Banerjee D,Sengupta S,Harfouche R

    更新日期:2012-09-22 00:00:00

  • Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells.

    abstract:BACKGROUND:Triple-negative breast cancers represent an important clinical challenge, as these cancers do not respond to conventional endocrine therapies or other available targeted agents. Phycocyanin (PC), a natural, water soluble and non-toxic molecule is shown to have potent anti-cancer property. METHODS:In this st...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-015-1784-x

    authors: Ravi M,Tentu S,Baskar G,Rohan Prasad S,Raghavan S,Jayaprakash P,Jeyakanthan J,Rayala SK,Venkatraman G

    更新日期:2015-10-23 00:00:00

  • Case-control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis.

    abstract:BACKGROUND:The causal association between persistent human papillomavirus (HPV) infection and cervical cancer has been established, but the mechanisms that favor HPV persistence in cervical cells are still unknown. The diminished capability of the immune system to control and resolve HPV infection is one of several hyp...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-618

    authors: Gillio-Tos A,Bicalho Mda G,Fiano V,Grasso C,Tarallo V,De Marco L,Trevisan M,Xavier M,Slowik R,Carvalho NS,Maestri CA,Lacerda HM,Zugna D,Richiardi L,Merletti F

    更新日期:2012-12-24 00:00:00

  • Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer.

    abstract:BACKGROUND:Wnt-2 plays an oncogenic role in cancer, but which Frizzled receptor(s) mediates the Wnt-2 signaling pathway in lung cancer remains unclear. We sought to (1) identify and evaluate the activation of Wnt-2 signaling through Frizzled-8 in non-small cell lung cancer, and (2) test whether a novel expression const...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-13-316

    authors: Bravo DT,Yang YL,Kuchenbecker K,Hung MS,Xu Z,Jablons DM,You L

    更新日期:2013-07-01 00:00:00

  • miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study.

    abstract:BACKGROUND:Altered expression of microRNAs (miRNAs) is known to contribute to cancer progression. miR-23b and miR-27b, encoded within the same miRNA cluster, are reported to have both tumor suppressive and oncogenic activity across human cancers, including breast cancer. METHODS:To clarify this dichotomous role in bre...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-5839-2

    authors: Hannafon BN,Cai A,Calloway CL,Xu YF,Zhang R,Fung KM,Ding WQ

    更新日期:2019-06-28 00:00:00

  • IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.

    abstract:BACKGROUND:We previously reported that IL-6 and transglutaminase 2 (TG2) were expressed in more aggressive basal-like breast cancer cells, and TG2 and IL-6 expression gave these cells stem-cell-like phenotypes, increased invasive ability, and increased metastatic potential. In the present study, the underlying mechanis...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2746-7

    authors: Oh K,Lee OY,Park Y,Seo MW,Lee DS

    更新日期:2016-09-08 00:00:00

  • Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.

    abstract:BACKGROUND:Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions of key cofactors, including nuclear receptor coactivator (NCOA), remain poorly understood in prostat...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2378-y

    authors: Takeda K,Hara N,Nishiyama T,Tasaki M,Ishizaki F,Tomita Y

    更新日期:2016-05-25 00:00:00

  • Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.

    abstract:BACKGROUND:Significant progress in treatment of metastatic castration resistant prostate cancer (mCRPC) has been made. Biomarkers to tailor therapy are scarce. To facilitate decision-making we evaluated dynamic changes of alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and prostate specific antigen (PSA) under ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2260-y

    authors: Mikah P,Krabbe LM,Eminaga O,Herrmann E,Papavassilis P,Hinkelammert R,Semjonow A,Schrader AJ,Boegemann M

    更新日期:2016-03-14 00:00:00

  • High Smac/DIABLO expression is associated with early local recurrence of cervical cancer.

    abstract:BACKGROUND:In a recent pilot report, we showed that Smac/DIABLO mRNA is expressed de novo in a subset of cervical cancer patients. We have now expanded this study and analyzed Smac/DIABLO expression in the primary lesions in 109 cervical cancer patients. METHODS:We used immunohistochemistry of formalin-fixed, paraffin...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-6-256

    authors: Arellano-Llamas A,Garcia FJ,Perez D,Cantu D,Espinosa M,De la Garza JG,Maldonado V,Melendez-Zajgla J

    更新日期:2006-10-26 00:00:00

  • Decreased expression of the β2 integrin on tumor cells is associated with a reduction in liver metastasis of colorectal cancer in mice.

    abstract:BACKGROUND:Lymphocyte Function-Associated Antigen-1 (LFA-1; CD18/CD11a) is one of the main adhesion molecules used by immune cells to infiltrate the liver under inflammatory conditions. Recently, the expression of this integrin has also been reported on several solid tumors, including colorectal cancer. However, its fu...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3823-2

    authors: Benedicto A,Marquez J,Herrero A,Olaso E,Kolaczkowska E,Arteta B

    更新日期:2017-12-06 00:00:00

  • Comparative benefit from small tumour size and adjuvant chemotherapy: clues for explaining breast cancer mortality decline.

    abstract:BACKGROUND:Breast cancer mortality steadily declined from the 1990s and this has been attributed to early detection and/or to improvements in therapy. Which of those two has had the greater impact is a subject of contention. METHODS:A database of 386 patients, enrolled in a randomized clinical trial on the effect of a...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-702

    authors: Demicheli R,Ambrogi F

    更新日期:2014-09-24 00:00:00

  • Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer.

    abstract:BACKGROUND:A disintegrin and metalloprotease 8 (ADAM8) has been reported to be associated with various malignancies. However, no studies have examined ADAM8 association in colorectal cancer (CRC). The aim of this study was to investigate the expression and function of ADAM8 in CRC. METHODS:Expression level of ADAM8 in...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-568

    authors: Yang Z,Bai Y,Huo L,Chen H,Huang J,Li J,Fan X,Yang Z,Wang L,Wang J

    更新日期:2014-08-07 00:00:00

  • Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

    abstract::Following publication of the original article [1], the authors reported the following errors in the article. ...

    journal_title:BMC cancer

    pub_type: 杂志文章,已发布勘误

    doi:10.1186/s12885-019-5831-x

    authors: Perez EA,de Haas SL,Eiermann W,Barrios CH,Toi M,Im YH,Conte PF,Martin M,Pienkowski T,Pivot XB,Burris HA 3rd,Stanzel S,Patre M,Ellis PA

    更新日期:2019-06-24 00:00:00

  • Tetratricopeptide repeat domain 9A is an interacting protein for tropomyosin Tm5NM-1.

    abstract:BACKGROUND:Tetratricopeptide repeat domain 9A (TTC9A) protein is a recently identified protein which contains three tetratricopeptide repeats (TPRs) on its C-terminus. In our previous studies, we have shown that TTC9A was a hormonally-regulated gene in breast cancer cells. In this study, we found that TTC9A was over-ex...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-8-231

    authors: Cao S,Ho GH,Lin VC

    更新日期:2008-08-12 00:00:00

  • Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.

    abstract:BACKGROUND:Non-muscle invasive bladder cancer (NMIBC) is usually treated with local therapy including transurethral resection of the bladder tumor and intravesical therapy depending on the stage of the tumor. NMIBC is a rarely a metastatic diseases with lymph node invasion in less of 10%. In the other hand meningeal ca...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3309-2

    authors: Teyssonneau D,Daste A,Dousset V,Hoepffner JL,Ravaud A,Gross-Goupil M

    更新日期:2017-05-11 00:00:00

  • Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.

    abstract:BACKGROUND:Nicotinamide phosphoribosyltransferase (NAMPT) enzyme acts as the major enzyme in the nicotinamide adenine dinucleotide (NAD) synthesis salvage pathway. Deregulation of NAD could be associated with progression of several cancers such as breast cancer. Here, the consequence of NAMPT inhibition by miR-154 was ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-6221-0

    authors: Bolandghamat Pour Z,Nourbakhsh M,Mousavizadeh K,Madjd Z,Ghorbanhosseini SS,Abdolvahabi Z,Hesari Z,Ezzati Mobasser S

    更新日期:2019-11-01 00:00:00

  • Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.

    abstract:BACKGROUND:Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage. Thus, the concomitant use of novel compounds represents a critical strategy to improve t...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2957-y

    authors: Caponigro F,Di Gennaro E,Ionna F,Longo F,Aversa C,Pavone E,Maglione MG,Di Marzo M,Muto P,Cavalcanti E,Petrillo A,Sandomenico F,Maiolino P,D'Aniello R,Botti G,De Cecio R,Losito NS,Scala S,Trotta A,Zotti AI,Bruzzese

    更新日期:2016-11-25 00:00:00

  • TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.

    abstract:BACKGROUND:Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The objective of the FASTRACK II clinical trial is to investigate the efficacy of SABR for pr...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4916-2

    authors: Siva S,Chesson B,Bressel M,Pryor D,Higgs B,Reynolds HM,Hardcastle N,Montgomery R,Vanneste B,Khoo V,Ruben J,Lau E,Hofman MS,De Abreu Lourenco R,Sridharan S,Brook NR,Martin J,Lawrentschuk N,Kron T,Foroudi F

    更新日期:2018-10-23 00:00:00

  • Assessment of cancers' diagnostic stage in a Deaf community - survey about 4363 Deaf patients recorded in French units.

    abstract:BACKGROUND:Deaf people represent 0.1% of the French population and their access to public health campaigns is limited due to their frequent illiteracy and the infrequent use of sign language in campaigns. There is also a lack of general health knowledge in spite of the existence of French Deaf Care Units (UASS). The ai...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3972-3

    authors: Druel V,Hayet H,Esman L,Clavel M,Rougé Bugat ME

    更新日期:2018-01-23 00:00:00

  • Non-invasively predicting differentiation of pancreatic cancer through comparative serum metabonomic profiling.

    abstract:BACKGROUND:The differentiation of pancreatic ductal adenocarcinoma (PDAC) could be associated with prognosis and may influence the choices of clinical management. No applicable methods could reliably predict the tumor differentiation preoperatively. Thus, the aim of this study was to compare the metabonomic profiling o...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3703-9

    authors: Wen S,Zhan B,Feng J,Hu W,Lin X,Bai J,Huang H

    更新日期:2017-11-02 00:00:00

  • Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study.

    abstract:BACKGROUND:Tyrosine kinase inhibitors are the first line standard of care for treatment of metastatic renal cell carcinoma (RCC). Accurate response assessment in the setting of antiangiogenic therapies remains suboptimal as standard size-related response criteria do not necessarily accurately reflect clinical benefit, ...

    journal_title:BMC cancer

    pub_type: 临床试验,杂志文章

    doi:10.1186/s12885-017-3371-9

    authors: Kelly-Morland C,Rudman S,Nathan P,Mallett S,Montana G,Cook G,Goh V

    更新日期:2017-06-02 00:00:00

  • Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.

    abstract:BACKGROUND:We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. METHODS:Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorbent assay. We examined ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3209-5

    authors: Ak G,Tada Y,Shimada H,Metintas S,Ito M,Hiroshima K,Tagawa M,Metintas M

    更新日期:2017-03-23 00:00:00

  • Silencing microRNA-330-5p increases MMP1 expression and promotes an invasive phenotype in oesophageal adenocarcinoma.

    abstract:BACKGROUND:Many patients diagnosed with oesophageal adenocarcinoma (OAC) present with advanced disease and approximately half present with metastatic disease. Patients with localised disease, who are managed with curative intent, frequently undergo neoadjuvant chemoradiotherapy. Unfortunately, ~ 70% of patients have li...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-5996-3

    authors: Bibby BAS,Miranda CS,Reynolds JV,Cawthorne CJ,Maher SG

    更新日期:2019-08-07 00:00:00

  • MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma.

    abstract:BACKGROUND:This study was performed to investigate the effect of microRNA-203 (miR-203) and ΔNp63 on cell proliferation and the functional connection between miR-203 and ΔNp63 in ESCC. METHODS:We employed 2 human ESCC cell lines, Eca109 and TE-1, as the model system. The effect of miR-203 and ΔNp63 on cell proliferati...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-11-57

    authors: Yuan Y,Zeng ZY,Liu XH,Gong DJ,Tao J,Cheng HZ,Huang SD

    更新日期:2011-02-07 00:00:00

  • Trauma-associated growth of suspected dormant micrometastasis.

    abstract:BACKGROUND:Cancer patients may harbor micrometastases that remain dormant, clinically undetectable during a variable period of time. A traumatic event or surgery may trigger the balance towards tumor growth as a result of associated angiogenesis, cytokine and growth factors release. CASE PRESENTATION:We describe a pat...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-5-94

    authors: El Saghir NS,Elhajj II,Geara FB,Hourani MH

    更新日期:2005-08-04 00:00:00

  • The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies.

    abstract:BACKGROUND:The historical basis and contemporary evidence for the use of immune strategies for prevention of malignancies are reviewed. Emphasis is focussed on the Febrile Infections and Melanoma (FEBIM) study on melanoma and on malignancies that seem to be related to an overexpression of human endogenous retrovirus K ...

    journal_title:BMC cancer

    pub_type: 历史文章,杂志文章,评审

    doi:10.1186/1471-2407-14-595

    authors: Krone B,Kölmel KF,Grange JM

    更新日期:2014-08-16 00:00:00

  • More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells.

    abstract:BACKGROUND:Brain-derived neurotrophic factor (BDNF) has been reported to promote tumorigenesis and progression in several human malignancies. The purpose of this study was to explore the function of BDNF in lung squamous cell carcinoma (SCC) and adenocarcinoma (ADC). METHODS:The expression of BDNF was examined in 110 ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2218-0

    authors: Zhang SY,Hui LP,Li CY,Gao J,Cui ZS,Qiu XS

    更新日期:2016-02-29 00:00:00

  • A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.

    abstract:BACKGROUND:Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America. METHODS:Eleven LS hereditary cancer registrie...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3599-4

    authors: Rossi BM,Palmero EI,López-Kostner F,Sarroca C,Vaccaro CA,Spirandelli F,Ashton-Prolla P,Rodriguez Y,de Campos Reis Galvão H,Reis RM,Escremim de Paula A,Capochin Romagnolo LG,Alvarez K,Della Valle A,Neffa F,Kalfayan PG,Spir

    更新日期:2017-09-05 00:00:00

  • A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.

    abstract:BACKGROUND:The number of Nigerian men presenting with benign prostatic hyperplasia is on the rise because of increase awareness about the ailment. With the renewed effort by the national health insurance scheme to cover the informal sector, it becomes imperative to determine the cost implication for managing Benign Pro...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2431-x

    authors: Udeh EI,Ofoha CG,Adewole DA,Nnabugwu II

    更新日期:2016-07-07 00:00:00

  • Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.

    abstract:BACKGROUND:BRCA1 and BRCA2 mutations explain approximately one-fifth of the inherited susceptibility in high-risk Finnish hereditary breast and ovarian cancer (HBOC) families. EMSY is located in the breast cancer-associated chromosomal region 11q13. The EMSY gene encodes a BRCA2-interacting protein that has been implic...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3488-x

    authors: Määttä KM,Nurminen R,Kankuri-Tammilehto M,Kallioniemi A,Laasanen SL,Schleutker J

    更新日期:2017-07-24 00:00:00